Melanotan II
Also known as: MT-II, MT2
Melanotan II is a catalog-expanded peptide entry in ProtoComp's source-backed compound corpus. It is included for search, calculator math, stack awareness, and future research curation based on expand compound catalog, local_seed, seed corpus peptides. Published dosing, cycle length, and clinical-use claims are intentionally left null until compound-specific evidence is reviewed.
Non-selective melanocortin receptor agonist. Research chemical — not approved for human use. Loading phase: low daily dose with gradual increase to assess tolerance.
Cycle off after pigmentation is achieved. Repeat use has been associated with changes in existing moles.
Off-cycle: 4 weeks
Nausea and flushing are most noticeable in the 1-2 hours post-dose.
Contraindications
- • History of melanoma or atypical nevi
- • Cardiovascular disease
- • Uncontrolled hypertension
Common side effects
- • Nausea (very common)
- • Flushing
- • Decreased appetite
- • Spontaneous erections
- • Focal hyperpigmentation
- • Darkening of existing moles
Serious risks
- • Reports of new melanocytic lesions and changes in existing moles
- • Not approved for human use
- • Quality and purity concerns with grey-market product
Requires monitoring
- • Full skin exam before and during use
Pregnancy / breastfeeding
Contraindicated
Male
Spontaneous erections during loading phase are common
- Not the same as Melanotan I (afamelanotide, Scenesse) — MT-II is non-selective and has more side effects
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.